FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080872787> ?p ?o ?g. }

• W2080872787 endingPage "56" @default.
• W2080872787 startingPage "50" @default.
• W2080872787 abstract "Pharmacokinetics, safety and antiviral activity of twice-daily fosamprenavir with or without ritonavir were evaluated in 2- to 18-year-old protease inhibitor-naïve and -experienced HIV-1-infected children.Serial pharmacokinetic samples were collected at week 2 and predose samples every 4-12 weeks. Safety and plasma HIV-1 RNA were monitored every 4-12 weeks.Twenty protease inhibitor-naïve 2- to <6-year-old subjects received antiretroviral treatment including unboosted fosamprenavir twice-daily, whereas 89 protease inhibitor-naïve and -experienced 2- to 18-year-old subjects received fosamprenavir/ritonavir-containing therapy twice-daily. Median fosamprenavir exposure was 891 days (range 15-1805 days), with 88% exposed >48 weeks. Twice-daily doses of fosamprenavir/ritonavir 23/3 mg/kg in 2- to <6-year olds, 18/3 mg/kg in ≥6-year olds and 700/100 mg in adolescents achieved plasma amprenavir exposures comparable with or higher than 700/100 mg twice-daily in adults while fosamprenavir 30 mg/kg twice-daily in 2- to <6-year olds led to exposures higher than 1400 mg twice-daily in adults. The proportion of subjects with HIV-1 RNA <400 copies/mL at week 48 was 60% for fosamprenavir and 53-74% for fosamprenavir/ritonavir (intent-to-treat [exposed], snapshot analysis). Median increases in absolute and relative (percentage) CD4 counts from baseline to week 48 occurred in both the fosamprenavir (340 cells/mm; 8%) and fosamprenavir/ritonavir group (190 cells/mm; 8%). The most common adverse events were vomiting, cough, and diarrhea; 18 subjects experienced serious adverse events, including 9 with suspected abacavir hypersensitivity.Fosamprenavir regimens administered to HIV-1-infected children aged 2-18 years were generally well-tolerated and provided sustained antiviral activity over 48 weeks, with plasma amprenavir exposures comparable with or higher than adults." @default.
• W2080872787 created "2016-06-24" @default.
• W2080872787 creator A5009272615 @default.
• W2080872787 creator A5013091354 @default.
• W2080872787 creator A5023532475 @default.
• W2080872787 creator A5027759958 @default.
• W2080872787 creator A5050767706 @default.
• W2080872787 creator A5058472962 @default.
• W2080872787 creator A5069581471 @default.
• W2080872787 creator A5077285894 @default.
• W2080872787 creator A5077320445 @default.
• W2080872787 creator A5086904732 @default.
• W2080872787 creator A5089080257 @default.
• W2080872787 creator A5090298589 @default.
• W2080872787 creator A5091022464 @default.
• W2080872787 date "2014-01-01" @default.
• W2080872787 modified "2023-10-15" @default.
• W2080872787 title "Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children" @default.
• W2080872787 cites W1971758213 @default.
• W2080872787 cites W1971771720 @default.
• W2080872787 cites W1984389793 @default.
• W2080872787 cites W2067059258 @default.
• W2080872787 cites W2073209229 @default.
• W2080872787 cites W2084180691 @default.
• W2080872787 cites W2109350540 @default.
• W2080872787 cites W2122986037 @default.
• W2080872787 cites W2126908085 @default.
• W2080872787 cites W2159943759 @default.
• W2080872787 doi "https://doi.org/10.1097/inf.0b013e3182a1126a" @default.
• W2080872787 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3882305" @default.
• W2080872787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23811744" @default.
• W2080872787 hasPublicationYear "2014" @default.
• W2080872787 type Work @default.
• W2080872787 sameAs 2080872787 @default.
• W2080872787 citedByCount "7" @default.
• W2080872787 countsByYear W20808727872014 @default.
• W2080872787 countsByYear W20808727872015 @default.
• W2080872787 countsByYear W20808727872016 @default.
• W2080872787 countsByYear W20808727872022 @default.
• W2080872787 crossrefType "journal-article" @default.
• W2080872787 hasAuthorship W2080872787A5009272615 @default.
• W2080872787 hasAuthorship W2080872787A5013091354 @default.
• W2080872787 hasAuthorship W2080872787A5023532475 @default.
• W2080872787 hasAuthorship W2080872787A5027759958 @default.
• W2080872787 hasAuthorship W2080872787A5050767706 @default.
• W2080872787 hasAuthorship W2080872787A5058472962 @default.
• W2080872787 hasAuthorship W2080872787A5069581471 @default.
• W2080872787 hasAuthorship W2080872787A5077285894 @default.
• W2080872787 hasAuthorship W2080872787A5077320445 @default.
• W2080872787 hasAuthorship W2080872787A5086904732 @default.
• W2080872787 hasAuthorship W2080872787A5089080257 @default.
• W2080872787 hasAuthorship W2080872787A5090298589 @default.
• W2080872787 hasAuthorship W2080872787A5091022464 @default.
• W2080872787 hasBestOaLocation W20808727871 @default.
• W2080872787 hasConcept C112705442 @default.
• W2080872787 hasConcept C126322002 @default.
• W2080872787 hasConcept C142462285 @default.
• W2080872787 hasConcept C159047783 @default.
• W2080872787 hasConcept C181199279 @default.
• W2080872787 hasConcept C185592680 @default.
• W2080872787 hasConcept C2776714187 @default.
• W2080872787 hasConcept C2777182164 @default.
• W2080872787 hasConcept C2777363262 @default.
• W2080872787 hasConcept C2777583353 @default.
• W2080872787 hasConcept C2779298103 @default.
• W2080872787 hasConcept C2780852908 @default.
• W2080872787 hasConcept C2781143361 @default.
• W2080872787 hasConcept C2993143319 @default.
• W2080872787 hasConcept C3013748606 @default.
• W2080872787 hasConcept C55493867 @default.
• W2080872787 hasConcept C71924100 @default.
• W2080872787 hasConcept C90924648 @default.
• W2080872787 hasConcept C98274493 @default.
• W2080872787 hasConceptScore W2080872787C112705442 @default.
• W2080872787 hasConceptScore W2080872787C126322002 @default.
• W2080872787 hasConceptScore W2080872787C142462285 @default.
• W2080872787 hasConceptScore W2080872787C159047783 @default.
• W2080872787 hasConceptScore W2080872787C181199279 @default.
• W2080872787 hasConceptScore W2080872787C185592680 @default.
• W2080872787 hasConceptScore W2080872787C2776714187 @default.
• W2080872787 hasConceptScore W2080872787C2777182164 @default.
• W2080872787 hasConceptScore W2080872787C2777363262 @default.
• W2080872787 hasConceptScore W2080872787C2777583353 @default.
• W2080872787 hasConceptScore W2080872787C2779298103 @default.
• W2080872787 hasConceptScore W2080872787C2780852908 @default.
• W2080872787 hasConceptScore W2080872787C2781143361 @default.
• W2080872787 hasConceptScore W2080872787C2993143319 @default.
• W2080872787 hasConceptScore W2080872787C3013748606 @default.
• W2080872787 hasConceptScore W2080872787C55493867 @default.
• W2080872787 hasConceptScore W2080872787C71924100 @default.
• W2080872787 hasConceptScore W2080872787C90924648 @default.
• W2080872787 hasConceptScore W2080872787C98274493 @default.
• W2080872787 hasIssue "1" @default.
• W2080872787 hasLocation W20808727871 @default.
• W2080872787 hasLocation W20808727872 @default.
• W2080872787 hasLocation W20808727873 @default.
• W2080872787 hasLocation W20808727874 @default.
• W2080872787 hasLocation W20808727875 @default.

• next